Yazar "Demir, Bilgin" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim Yok
    Öğe
    Mauriac Syndrome: Case Report and Review of the Literature
    (Galenos Yayincilik, 2017) Topaloglu, Omercan; Sezer, Sibel Demiral; Demir, Bilgin; Akarken, Derya
    This is a case report of a young male with poorly controlled type 1 diabetes mellitus who presented with the clinical features of diabetic ketoacidosis. Once the patient was stabilized, he was examined for hepatomegaly and elevated liver enzymes. Along with the other clinical features, the patient was diagnosed as a case of Mauriac Syndrome. Mauriac Syndrome, initially described by Mauriac in 1930, is one of the causes of hepatomegaly and elevated liver enzymes in poorly controlled diabetic patients. However, hepatomegaly, growth retardation and other clinical features of the syndrome have been found to be reversible with optimization of insulin therapy. In patients with poorly controlled diabetes, Type 1 diabetic patients must be closely observed for sexual maturation and growth. After optimal therapy has been given, close follow-up is essential to observe the regression of clinical features.
  • Küçük Resim Yok
    Öğe
    May ischemia modified albumin be a predictor in diagnosis of contrast induced nephropathy?
    (2018) Topaloğlu, Ömercan; Demir, Bilgin; Ekinci, Ferhat; Uzun, Mehmet; Kurtulmuş, Yusuf; Turkon, Hakan; Duman, Can
    Aim: “Ischemia modified albumin” (IMA) was investigated as a possible biomarker in several diseases such as vascular disorders. We aimed to reveal the possible value of IMA in predicting the development of contrast induced nephropathy (CIN) after coronary angiography in patients with stable angina pectoris.Material and Methods: 106 patients underwent coronary angiography with a diagnosis of stable angina pectoris were included in our study. Basic demographic and clinical findings and laboratory values were recorded and analyzed. Serum creatinine (SCre) levels were also measured 48 hours after coronary angiography and recorded. Amount of contrast agent (CA) given during coronary angiography was recorded. The patients were divided into 2 groups: CIN positive and CIN negative groups.Results: CIN was developed in 14 patients (13%); and IMA levels were similar in CIN positive and negative groups (p>0.05). SCre (both measurements before and after CA administration) was not correlated with IMA levels. There was no association between drug usage and development of CIN (p>0.05). Comorbidities were not associated with the development of CIN (p>0.05) with the exception of hypertension (HT). Presence of hypertension (p=0.0393) and female gender (p=0.0199) was associated with development of CIN. Mean age was 61.3 and 52.3 in CIN positive and negative groups, respectively (p>0.05).Conclusion: Any specific biomarker indicating CIN is not available yet. Most frequently used marker is the measurement of SCre 24- 48 hours after administration of CA. We found IMA levels not to be a predictor for the development of CIN. Further investigations will clearly determine the importance of IMA as a biomarker in renal failure developed after CA administration.
  • Küçük Resim
    Öğe
    May ischemia modified albumin be a predictor in diagnosis of contrast induced nephropathy?
    (2018) Topaloglu, Omercan; Demir, Bilgin; Ekinci, Ferhat; Uzun, Mehmet; Kurtulmus, Yusuf; Turkon, Hakan; Duman, Cem; Akar, Harun; Tanrisev, Mehmet
    Aim: “Ischemia modified albumin” (IMA) was investigated as a possible biomarker in several diseases such as vascular disorders. We aimed to reveal the possible value of IMA in predicting the development of contrast induced nephropathy (CIN) after coronary angiography in patients with stable angina pectoris. Material and Methods: 106 patients underwent coronary angiography with a diagnosis of stable angina pectoris were included in our study. Basic demographic and clinical findings and laboratory values were recorded and analyzed. Serum creatinine (SCre) levels were also measured 48 hours after coronary angiography and recorded. Amount of contrast agent (CA) given during coronary angiography was recorded. The patients were divided into 2 groups: CIN positive and CIN negative groups. Results: CIN was developed in 14 patients (13%); and IMA levels were similar in CIN positive and negative groups (p>0.05). SCre (both measurements before and after CA administration) was not correlated with IMA levels. There was no association between drug usage and development of CIN (p>0.05). Comorbidities were not associated with the development of CIN (p>0.05) with the exception of hypertension (HT). Presence of hypertension (p=0.0393) and female gender (p=0.0199) was associated with development of CIN. Mean age was 61.3 and 52.3 in CIN positive and negative groups, respectively (p>0.05). Conclusion: Any specific biomarker indicating CIN is not available yet. Most frequently used marker is the measurement of SCre 24- 48 hours after administration of CA. We found IMA levels not to be a predictor for the development of CIN. Further investigations will clearly determine the importance of IMA as a biomarker in renal failure developed after CA administration.